Ionis Pharmaceuticals Inc IONS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

11

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

O'neil Patrick R.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

246

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Monia Brett P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

140

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

11

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Birchler Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

12

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Bennett C Frank

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

177

Price:

$38.64
Aug 29, 2024 (filed on Sep 03, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-331

Price:

$49.63
Aug 28, 2024 (filed on Sep 03, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-320

Price:

$49.16
Aug 05, 2024 (filed on Aug 06, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,430

Price:

$48.00
Jul 16, 2024 (filed on Jul 17, 2024)

Insider Name:

Klein Joseph III

Ownership Type:

Indirect Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-12,000

Price:

--

Filings by filing date

Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

11

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

O'neil Patrick R.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

246

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Monia Brett P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

140

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

11

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Birchler Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

12

Price:

$38.64
Aug 30, 2024 (filed on Sep 04, 2024)

Insider Name:

Bennett C Frank

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

177

Price:

$38.64
Feb 02, 2024 (filed on Sep 04, 2024)

Insider Name:

Geary Richard S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,995

Price:

$50.04
Feb 02, 2024 (filed on Sep 04, 2024)

Insider Name:

Hougen Elizabeth L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,162

Price:

$49.54
Feb 02, 2024 (filed on Sep 04, 2024)

Insider Name:

O'neil Patrick R.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,995

Price:

$49.67
Feb 02, 2024 (filed on Sep 04, 2024)

Insider Name:

Schneider Eugene

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,106

Price:

$49.59

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	2855 Gazelle Court CARLSBAD CA 92010
Tel:	N/A
Website:	https://www.ionispharma.com
IR:	See website

Key People

Brett P. Monia Chief Executive Officer, Director	Elizabeth L. Hougen Chief Financial Officer, Executive Vice President - Finance	C. Frank Bennett Executive Vice President, Chief Scientific Officer
Joseph T. Baroldi Executive Vice President, Chief Business Officer	Richard S. Geary Executive Vice President, Chief Development Officer	Kyle Jenne Executive Vice President - commercial
Eugene Schneider Executive Vice President, Chief Clinical Development and Operations Officer	Eric E. Swayze Executive Vice President - Research	Patrick R. O'Neil Chief Legal Officer, General Counsel and Corporate Secretary

Business Overview

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Financial Overview

For the six months ended 30 June 2024, Ionis Pharmaceuticals Inc revenues increased 8% to $344.7M. Net loss increased less than 1% to $209.1M. Revenues reflect Ionis operations segment increase of 83% to $344.7M., offset by Ionis operations segment loss increase from $90.2M to $215.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.47 to -$1.44.

Employees:	927 as of Feb 15, 2024

Reporting Currency:	U.S. Dollars
Enterprise value:	$6,054M as of Jun 30, 2024
Annual revenue (TTM):	$813.46M as of Jun 30, 2024
EBITDA (TTM):	-$332.34M as of Jun 30, 2024
Net annual income (TTM):	-$365.74M as of Jun 30, 2024
Free cash flow (TTM):	-$358.02M as of Jun 30, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	146,211,091 as of Jul 26, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization